CoChat

Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer

Open access
Fakih, M., Vincent, M. · 2010 · Current Oncology
Cited by 109

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis, and angiogenesis. EGFR is overexpressed in a variety of solid tumors, including colorectal cancer (CRC), and its overexpression is associated with poorer prognosis. One class of agents that is currently used to target EGFR in the treatment of metastatic CRC (mCRC) is the monoclonal antibodies. While the monoclonal antibody EGFR inhibitors lack many of the severe side effects commonly observed with cytotoxic chemotherapy, they are associated with a set of unique dermatological toxicities. This paper reviews the safety profile of the anti-EGFR monoclonal antibodies cetuximab and panitumumab in the treatment of mCRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3747/co.v17is1.615

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 90

  1. Albanese, 1992, Expression of epidermal growth factor receptor and transforming growth factor alpha in human larynx carcinoma, Cancer Lett., 65, 189, 10.1016/0304-3835(92)90231-J · DOI
  2. Salomon, 1995, Epidermal growth factor-related peptides and their receptors in human malignancies, Crit Rev Oncol Hematol., 19, 183, 10.1016/1040-8428(94)00144-I · DOI · Paper page
  3. Miettinen, 1995, Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor, Nature., 376, 337, 10.1038/376337a0 · DOI · Paper page
  4. Klapper, 2000, Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors, Adv Cancer Res., 77, 25, 10.1016/S0065-230X(08)60784-8 · DOI · Paper page
  5. Alroy, 1997, The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions, FEBS Lett., 410, 83, 10.1016/S0014-5793(97)00412-2 · DOI · Paper page
  6. Yarden, 2001, The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities, Eur J Cancer., 37, S3, 10.1016/S0959-8049(01)00230-1 · DOI · Paper page
  7. Castillo, 2004, Pharmacological background of EGFR targeting, Ann Oncol., 15, 1007, 10.1093/annonc/mdh257 · DOI
  8. Ciardiello, 2001, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor, Clin Cancer Res., 7, 2958
  9. Mayer, 1993, The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer, Cancer., 71, 2454, 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2 · DOI · Paper page
  10. Nicholson, 2001, EGFR and cancer prognosis, Eur J Cancer., 37, S9, 10.1016/S0959-8049(01)00231-3 · DOI · Paper page
  11. Ciardiello, 2002, An update of new targets for cancer treatment: receptor-mediated signals, Ann Oncol., 13, 29, 10.1093/annonc/mdf635 · DOI
  12. Zlobec, 2007, A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy, Br J Cancer., 96, 793, 10.1038/sj.bjc.6603619 · DOI
  13. Gross, 1991, Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient, Cancer Res., 51, 1452
  14. Radinsky, 1995, Modulation of tumour cell gene expression and phenotype by the organ-specific metastatic environment, Cancer Metastasis Rev., 14, 323, 10.1007/BF00690601 · DOI
  15. Radinsky, 1995, Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells, Clin Cancer Res., 1, 19
  16. Prewett, 2002, Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts, Clin Cancer Res., 8, 994
  17. Mendelsohn, 2003, Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer, J Clin Oncol., 21, 2787, 10.1200/JCO.2003.01.504 · DOI · Paper page
  18. Mitchell, 2007, Clinical presentation and pathophysiology of EGFRI dermatologic toxicities, Oncology (Williston Park)., 21, 4
  19. Lacouture, 2005, Mechanisms of cutaneous toxicities to EGFR inhibitors, Nature Rev Cancer., 6, 803, 10.1038/nrc1970 · DOI · Paper page
  20. Lacouture, 2007, Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective, Skin Therapy Lett., 12, 1
  21. Segaert, 2005, The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies, J Dtsch Dermatol Ges., 3, 599, 10.1111/j.1610-0387.2005.05058.x · DOI
  22. Segaert, 2005, Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors, Ann Oncol., 16, 1425, 10.1093/annonc/mdi279 · DOI · Paper page
  23. Folprecht, 2006, Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma, Ann Oncol., 17, 450, 10.1093/annonc/mdj084 · DOI · Paper page
  24. Busam, 2001, Cutaneous sideeffects in cancer patients treated with the antiepidermal growth factor receptor antibody C225, Br J Dermatol., 144, 1169, 10.1046/j.1365-2133.2001.04226.x · DOI · Paper page
  25. Molinari, 2005, Cetuximabinduced acne, Dermatology., 211, 330, 10.1159/000088502 · DOI
  26. Bertin, 2005, Trichomegaly of the eyelashes following treatment with cetuximab, Ann Oncol., 16, 1711, 10.1093/annonc/mdi300 · DOI
  27. Boucher, 2002, Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody, J Am Acad Dermatol., 47, 632, 10.1067/mjd.2002.124621 · doi:10.1067/mjd.2002.124621
  28. Grenader, 2008, Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity, Clin Lung Cancer., 9, 59, 10.3816/CLC.2008.n.010 · DOI
  29. Peeters, 2009, Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?, Oncologist., 14, 29, 10.1634/theoncologist.2008-0167 · DOI
  30. Tol, 2008, A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity, Ann Oncol., 19, 734, 10.1093/annonc/mdm607 · DOI · Paper page
  31. Saltz, 2007, L.; et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared With cetuximab and bevacizumab alone in irinotecanrefractory colorectal cancer: the BOND-2 study, Clin Oncol., 25, 4557
  32. Jacot, 2004, Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours, Br J Dermatol., 151, 238, 10.1111/j.1365-2133.2004.06026.x · doi:10.1111/j.1365-2133.2004.06026.x
  33. Bianchini, 2008, Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker, Clin Colorectal Cancer., 7, 33, 10.3816/CCC.2008.n.005 · DOI
  34. Mitchell, E.P., LaCouture, M., and Shearer, H. Updated results of STEPP, a phase 2, open-label study of pre-emptive versus reactive skin toxicity treatment in metastatic colorectal cancer (mCRC) patients receiving panitumumab+FOLFIRI or irinotecan-only chemotherapy as second-line treatment. European Society for Medical Oncology (ESMO) International Symposium. 10th World Congress on Gastrointestinal Cancer; June 25–28, 2008; Barcelona, Spain. (Abstract O-021) Available online at: www.worldgicancer.com/WCGI/WGIC08/WGIC08_press- info_combined.pdf; cited December 15, 2008. · doi:10.1200/jco.2008.26.15_suppl.15007
  35. Lacouture, 2007, Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer, Cancer Nurs., 30, S17, 10.1097/01.NCC.0000281758.85704.9b · DOI
  36. Foon, 2004, Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody, Int J Radiat Oncol Biol Phys., 58, 984, 10.1016/j.ijrobp.2003.09.098 · DOI · Paper page
  37. Rowinsky, 2004, Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer, J Clin Oncol., 22, 3003, 10.1200/JCO.2004.11.061 · DOI · Paper page
  38. Jih, 2002, Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors, Arch Dermatol., 138, 129, 10.1001/archderm.138.1.129 · DOI
  39. Walon, 2003, [Acneiform eruptions induced by cetuximab], Ann Dermatol Venereol., 130, 443
  40. Lenz, 2006, Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines, J Clin Oncol., 24, 4914, 10.1200/JCO.2006.06.7595 · DOI · Paper page
  41. Siena, 2008, An open-label, singlearm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy, Ann Oncol., 19, 92, 10.1093/annonc/mdm399 · DOI
  42. Nowacki, 2007, Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial, J Clin Oncol., 25, 4000, 10.1200/jco.2007.25.18_suppl.4000 · DOI · Paper page
  43. Hecht, 2007, Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer, Cancer., 110, 980, 10.1002/cncr.22915 · DOI · Paper page
  44. Tejpar, 2007, Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data, J Clin Oncol., 25, 4037, 10.1200/jco.2007.25.18_suppl.4037 · DOI · Paper page
  45. Melosky, 2009, Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations, Curr Oncol., 16, 16, 10.3747/co.v16i1.361 · DOI
  46. Scope, 2007, Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption, J Clin Oncol., 25, 5390, 10.1200/JCO.2007.12.6987 · DOI · Paper page
  47. Mitchell, 2008, A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan-only chemotherapy (CT) as 2nd-line treatment (tx): Interim analysis, J Clin Oncol., 26, 15007, 10.1200/jco.2008.26.15_suppl.15007 · doi:10.1200/jco.2008.26.15_suppl.15007
  48. Grothey, 2006, Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer, Oncology (Williston Park)., 20, 21
  49. Agero, 2006, Dermatologic side effects associated with the epidermal growth factor receptor inhibitors, J Am Acad Dermatol., 55, 657, 10.1016/j.jaad.2005.10.010 · DOI · Paper page
  50. 2006, Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer, Clin Lung Cancer, 8, S7, 10.3816/CLC.2006.s.008 · DOI
  51. Porzio, 2006, Efficacy of pregabalin in the management of cetuximab-related itch, J Pain Symptom Manage., 32, 397, 10.1016/j.jpainsymman.2006.07.006 · doi:10.1016/j.jpainsymman.2006.07.006
  52. Lynch, 2007, Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management, Oncologist., 12, 610, 10.1634/theoncologist.12-5-610 · DOI · Paper page
  53. Dick, 2005, Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors, Commun Oncol., 2, 492, 10.1016/S1548-5315(11)70630-1 · DOI
  54. Marcuello, 2006, Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients, J Am Acad Dermatol., 55, 429, 10.1016/j.jaad.2006.04.062 · DOI
  55. Chang, 2004, Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer, J Clin Oncol., 22, 4646, 10.1200/JCO.2004.02.168 · doi:10.1200/jco.2004.02.168
  56. Shah, 2005, Practical management of patients with non-small-cell lung cancer treated with gefitinib, J Clin Oncol., 23, 165, 10.1200/JCO.2005.04.057 · DOI · Paper page
  57. Dainichi, 2003, Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor, Dermatology., 207, 324, 10.1159/000073100 · doi:10.1159/000073100
  58. Nakano, 2003, Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, J Dermatol., 30, 261, 10.1111/j.1346-8138.2003.tb00387.x · doi:10.1111/j.1346-8138.2003.tb00387.x
  59. Dueland, 2003, Epidermal growth factor receptor inhibition induces trichomegaly, Acta Oncol., 42, 345, 10.1080/02841860310006038 · DOI
  60. Pascual, 2004, Trichomegaly following treatment with gefitinib (ZD1839), Br J Dermatol., 151, 1111, 10.1111/j.1365-2133.2004.06265.x · doi:10.1111/j.1365-2133.2004.06265.x
  61. Drelich, 2007, Dermatological toxicities of panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC) from three clinical studies, J Clin Oncol, 25, 14551, 10.1200/jco.2007.25.18_suppl.14551 · doi:10.1200/jco.2007.25.18_suppl.14551
  62. Lacouture, 2006, The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors, J Support Oncol., 4, 236
  63. Berger, 2008, Severe skin reaction secondary to concomitant radiotherapy plus cetuximab, Radiat Oncol., 3, 5, 10.1186/1748-717X-3-5 · DOI
  64. Gerber, 2008, Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab, Strahlenther Onkol., 184, 105, 10.1007/s00066-008-1829-z · doi:10.1007/s00066-008-1829-z
  65. Azad, 2009, Severe cutaneous toxicity following treatment with radiotherapy and cetuximab: a case report, Cases J., 2, 25, 10.1186/1757-1626-2-25 · doi:10.1186/1757-1626-2-25
  66. Giro, 2009, High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes, Radiother Oncol., 90, 166, 10.1016/j.radonc.2008.09.007 · DOI
  67. Pryor, 2009, Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer, Radiother Oncol., 90, 172, 10.1016/j.radonc.2008.09.018 · doi:10.1016/j.radonc.2008.09.018
  68. Bonner, 2006, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med., 354, 567, 10.1056/NEJMoa053422 · DOI · Paper page
  69. Tonini, 2005, Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient, J Natl Cancer Inst., 97, 606, 10.1093/jnci/dji104 · DOI
  70. Dranko, 2006, Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer, Clin Colorectal Cancer., 6, 224, 10.3816/CCC.2006.n.040 · DOI
  71. Tejpar, 2007, Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study, Lancet Oncol., 8, 387, 10.1016/S1470-2045(07)70108-0 · DOI · Paper page
  72. Sobrero, 2008, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol., 26, 2311, 10.1200/JCO.2007.13.1193 · DOI · Paper page
  73. Jonker, D.J., Karapetis, C.S., and Moore, M. Randomized phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG) [abstract]. Presented at the American Association for Cancer Research Annual Meeting; April 14–18, 2007, Los Angeles, CA. In: Program and proceedings of the 2007 annual meeting of the American Association for Cancer Research. Philadelphia, PA: American Association for Cancer Research, 2007.
  74. Giusti, 2007, FDA drug approval summary: panitumumab (Vectibix), Oncologist., 12, 577, 10.1634/theoncologist.12-5-577 · DOI · Paper page
  75. Saif, 2006, Role of panitumumab in the management of metastatic colorectal cancer, Clin Colorectal Cancer., 6, 118, 10.3816/CCC.2006.n.028 · DOI
  76. Saif, 2008, Management of hypomagnesemia in cancer patients receiving chemotherapy, J Support Oncol., 6, 243
  77. Schrag, 2005, Cetuximab therapy and symptomatic hypomagnesemia, J Natl Cancer Inst., 97, 1221, 10.1093/jnci/dji242 · DOI · Paper page
  78. Peeters, 2006, Panitumumab significantly improves progression-free survival in patients with metastatic colorectal cancer, Ann Oncol, 17, vi19
  79. Fakih, 2006, Cetuximab-induced hypomagnesemia in patients with colorectal cancer, Clin Colorectal Cancer., 6, 152, 10.3816/CCC.2006.n.033 · DOI
  80. Kuo, 2005, Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer, J Clin Oncol., 23, 5613, 10.1200/JCO.2005.08.359 · DOI
  81. Iannello, 2001, Hypomagnesemia. A review of pathophysiological, clinical and therapeutical aspects, Panminerva Med., 43, 177
  82. Fakih, 2008, Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia, Oncology (Williston Park)., 22, 74
  83. Berlin, 2007, Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer, Clin Colorectal Cancer., 6, 427, 10.3816/CCC.2007.n.011 · DOI
  84. Maroun, 2007, Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea, Curr Oncol., 14, 13, 10.3747/co.2007.96 · DOI · Paper page
  85. Allen, 2007, High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history, J Clin Oncol., 25, 3644, 10.1200/JCO.2007.11.7812 · DOI · Paper page
  86. Needle, 2002, Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody, Semin Oncol., 29, 55, 10.1053/sonc.2002.35648 · DOI
  87. Nielsen, 2006, Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports, Acta Oncol., 45, 1137, 10.1080/02841860600871764 · doi:10.1080/02841860600871764
  88. Siena, 2007, Infusion-related reactions (IRR) associated with cetuximab plus irinotecan treatment in patients with irinotecan-resistant metastatic colorectal cancer (mCRC): Findings from the MABEL study, J Clin Oncol., 25, 4137, 10.1200/jco.2007.25.18_suppl.4137 · DOI
  89. Saif, 2009, Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer, Cancer Chemother Pharmacol., 65, 107, 10.1007/s00280-009-1009-6 · DOI
  90. Saif, 2009, Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature, Cancer Chemother Pharmacol., 63, 1017, 10.1007/s00280-008-0831-6 · DOI

Cited by

See all 109

Metadata

Authors
Fakih, M., & Vincent, M.
Venue
Current Oncology
Publisher
MDPI AG
Published
2010-07-01
Volume
17
Issue
11
Pages
18-30
ISSN
1718-7729
OpenAlex
W2081820230
Cited by
109
References
22
FWCI
3.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.3747/co.v17is1.615
The paper
Fakih, M., & Vincent, M. (2010). Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer. Current Oncology. https://doi.org/10.3747/co.v17is1.615

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.